Unraveling the Complexities of Polycystic Ovarian Syndrome: A Comprehensive Review

Archana Kumari*1, Satya Narayan jha2
1Department of Biochemistry, Science College Patna University, Patna, Bihar, 144411, India
2Harsha Payi Singh College, Madhepur, Bihar, 847408, India
*Corresponding Author: ajha0103@gmail.com

ARTICLE INFO
Article history:
Received 25 March 2024
Revised 28 April 2024
Accepted 1 May 2024
Available online 1 May 2024
E-ISSN: 2622-1357
P-ISSN: 2622-9234

How to cite:

ABSTRACT
Polycystic Ovarian Syndrome (PCOS) is a complex endocrine disorder affecting reproductive-age women, characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. This comprehensive review delves into the multifaceted nature of PCOS, exploring its etiology, pathophysiology, clinical manifestations, diagnostic criteria, and management strategies. Key topics include the role of insulin resistance and hyperinsulinemia in PCOS pathogenesis, the impact of hormonal imbalances on menstrual irregularities and fertility, and the association of PCOS with metabolic syndrome and cardiovascular risk factors. Furthermore, the review discusses current diagnostic criteria and controversies surrounding PCOS diagnosis, as well as evidence-based approaches to treatment, encompassing lifestyle modifications, pharmacological interventions, and assisted reproductive technologies. By synthesizing current knowledge and emerging research findings, this review aims to provide a comprehensive overview of PCOS for clinicians, researchers, and individuals affected by this prevalent endocrine disorder.

Keywords: Fertility, Hyperandrogenism, Insulin Resistance, Ovulatory Dysfunction, PCOS

1. Introduction
Polycystic Ovarian Syndrome (PCOS) is a prevalent endocrine disorder affecting reproductive-age women, characterized by hormonal imbalances, ovulatory dysfunction, and polycystic ovaries. PCOS is a multifaceted condition with a complex etiology involving genetic, hormonal, and environmental factors [1]. This essay explores the definition of PCOS, its clinical manifestations, and the underlying etiological mechanisms contributing to its development.

What is PCOS?
Polycystic Ovarian Syndrome (PCOS) is a common endocrine disorder affecting approximately 5-10% of women of reproductive age worldwide. PCOS is characterized by a constellation of symptoms, including hyperandrogenism (elevated levels of male hormones), menstrual irregularities (oligomenorrhea or amenorrhea), and polycystic ovarian morphology observed on ultrasound imaging [1]. The Rotterdam criteria, established in 2003, are widely used for diagnosing PCOS and require the presence of at least two out of three criteria: oligo-ovulation or anovulation, clinical and/or biochemical signs of hyperandrogenism, and polycystic ovarian morphology on ultrasound.

Clinical Manifestations of PCOS:
PCOS presents with a diverse range of clinical manifestations, which may vary in severity among affected
individuals. Common symptoms of PCOS include irregular menstrual cycles, oligomenorrhea (infrequent menstrual periods), amenorrhea (absence of menstrual periods), hirsutism (excessive hair growth), acne, and male-pattern baldness (androgenic alopecia). Many women with PCOS also experience infertility due to anovulation or irregular ovulation, which can impair fertility and complicate conception [2-3].

Etiology of PCOS:
Polycystic Ovarian Syndrome (PCOS) is a complex endocrine disorder that affects a significant portion of reproductive-age women worldwide. While the exact etiology of PCOS remains incompletely understood, it is widely recognized as a multifactorial condition influenced by genetic, hormonal, and environmental factors. This essay aims to explore the various components of PCOS etiology, including genetic predisposition, hormonal imbalances, and environmental influences [4-7].

Genetic Factors: Family and twin studies have provided compelling evidence for a genetic predisposition to PCOS. First-degree relatives of affected individuals have a higher prevalence of PCOS compared to the general population, suggesting a familial clustering of the disorder. Genome-wide association studies (GWAS) have identified numerous susceptibility loci associated with PCOS, shedding light on the genetic basis of the condition. These loci encompass genes involved in various biological pathways relevant to PCOS pathogenesis, including steroidogenesis, insulin signaling, gonadotropin regulation, and ovarian function. Variants in genes encoding enzymes involved in androgen biosynthesis, such as CYP11A1 and CYP17A1, have been implicated in PCOS development, leading to hyperandrogenism and associated clinical manifestations [8]. Additionally, genetic polymorphisms affecting insulin signaling pathways, such as INSR and IRS1, may contribute to insulin resistance and hyperinsulinemia observed in women with PCOS.

Hormonal Imbalances: PCOS is characterized by dysregulation of the hypothalamic-pituitary-ovarian (HPO) axis, leading to hormonal imbalances that underlie its clinical features. Disrupted gonadotropin-releasing hormone (GnRH) secretion results in elevated levels of luteinizing hormone (LH) relative to follicle-stimulating hormone (FSH), contributing to aberrant follicular development and anovulation [9]. Hyperinsulinemia and insulin resistance, common metabolic features of PCOS, further exacerbate hormonal dysregulation by stimulating ovarian androgen production and reducing sex hormone-binding globulin (SHBG) levels, leading to increased bioavailability of free androgens. Elevated levels of androgens, including testosterone and dehydroepiandrosterone sulfate (DHEAS), promote the development of clinical manifestations such as hirsutism, acne, and androgenic alopecia. Moreover, imbalances in estrogen and progesterone levels contribute to menstrual irregularities, including oligomenorrhea and amenorrhea, observed in women with PCOS [10].

Environmental Factors: In addition to genetic and hormonal factors, environmental influences play a significant role in PCOS etiology. Lifestyle factors such as diet, physical activity, and body weight have been implicated in the development and progression of PCOS. Obesity, particularly central adiposity, exacerbates insulin resistance and hyperandrogenism, contributing to metabolic dysfunction and reproductive complications in women with PCOS [8-9]. Dietary factors, including high-calorie intake, excessive consumption of refined carbohydrates, and low intake of fiber and micronutrients, may further exacerbate insulin resistance and hormonal imbalances. Additionally, exposure to endocrine-disrupting chemicals (EDCs) in the environment, such as bisphenol A (BPA), phthalates, and polychlorinated biphenyls (PCBs), has been associated with PCOS development by disrupting hormonal signaling pathways and ovarian function [10]. These environmental factors interact with genetic predispositions to modulate PCOS risk and severity, highlighting the importance of a comprehensive approach to understanding PCOS etiology.

Gene-Environment Interactions: Interactions between genetic and environmental factors play a crucial role in shaping PCOS susceptibility and phenotype variability. Genetic predisposition may modulate individual responses to environmental exposures, influencing disease risk and expression. For example, individuals with specific genetic variants associated with insulin resistance or androgen biosynthesis may be more susceptible to the adverse effects of obesity or EDC exposure on PCOS development. Conversely, lifestyle modifications, such as diet and exercise interventions, may mitigate genetic predispositions and reduce PCOS risk by improving metabolic health and hormonal balance [8]. Understanding the complex interplay between genetic and environmental factors is essential for elucidating PCOS etiology and developing targeted prevention and management strategies tailored to individual risk profiles.

Polycystic Ovarian Syndrome (PCOS) is a multifactorial disorder influenced by genetic, hormonal, and environmental factors. Insulin resistance and hyperinsulinemia contribute to PCOS pathogenesis by disrupting ovarian function and hormonal balance, while hormonal imbalances, including hyperandrogenism and estrogen/progesterone dysregulation, underlie the clinical manifestations and reproductive complications
associated with the disorder [11]. Genetic predisposition and environmental influences, including lifestyle factors and EDC exposure, interact to shape PCOS susceptibility and phenotype variability.

**Role of Insulin Resistance and Hyperinsulinemia in PCOS:**
Insulin resistance and hyperinsulinemia play pivotal roles in the pathogenesis of Polycystic Ovarian Syndrome (PCOS), contributing to the development and progression of the disorder. Insulin resistance refers to impaired cellular response to insulin, leading to compensatory hyperinsulinemia, wherein the pancreas secretes excess insulin to maintain normoglycemia. In women with PCOS, insulin resistance is a common metabolic feature observed in up to 70-80% of cases [12]. This section explores the mechanisms underlying insulin resistance and hyperinsulinemia in PCOS and their impact on ovarian function and hormonal balance.

**Mechanisms of Insulin Resistance:**
Insulin resistance in PCOS is characterized by impaired insulin signaling pathways in peripheral tissues, such as adipose tissue, liver, and skeletal muscle. Several mechanisms contribute to insulin resistance in PCOS, including:

**Adipose Tissue Dysfunction:** Adipose tissue plays a crucial role in insulin sensitivity regulation through the secretion of adipokines, including adiponectin and leptin. In women with PCOS, adipose tissue dysfunction, characterized by adipocyte hypertrophy, inflammation, and altered adipokine secretion, contributes to insulin resistance. Elevated levels of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), impair insulin signaling pathways, leading to insulin resistance [13].

**Hepatic Insulin Resistance:** Hepatic insulin resistance results in increased hepatic glucose production (gluconeogenesis) and decreased glycogen synthesis, contributing to hyperglycemia and compensatory hyperinsulinemia. Hepatic insulin resistance in PCOS is mediated by dysregulation of insulin receptor signaling pathways, leading to impaired suppression of gluconeogenic gene expression and increased hepatic glucose output [14].

**Skeletal Muscle Insulin Resistance:** Skeletal muscle is the primary site for insulin-stimulated glucose uptake and disposal. Insulin resistance in skeletal muscle impairs glucose uptake and utilization, leading to reduced glucose disposal rates and elevated blood glucose levels. Defects in insulin receptor signaling, glucose transporter (GLUT4) expression, and intracellular glucose metabolism contribute to skeletal muscle insulin resistance in PCOS [13].

**Impact of Hyperinsulinemia on Ovarian Function:**
Hyperinsulinemia exerts direct and indirect effects on ovarian function, contributing to the pathogenesis of PCOS. Insulin acts synergistically with luteinizing hormone (LH) to stimulate ovarian androgen production by theca cells and inhibit follicular maturation and granulosa cell aromatase activity. Hyperinsulinemia promotes ovarian androgen excess by enhancing androgen synthesis and reducing sex hormone-binding globulin (SHBG) production, leading to increased bioavailability of free androgens [15]. Elevated androgen levels disrupt follicular development, impair oocyte quality, and contribute to anovulation and menstrual irregularities observed in women with PCOS.

Moreover, hyperinsulinemia stimulates ovarian insulin-like growth factor 1 (IGF-1) production, which promotes follicular growth and development. Excessive ovarian IGF-1 signaling may contribute to follicular arrest, cyst formation, and polycystic ovarian morphology observed on ultrasound imaging in women with PCOS [15]. Additionally, hyperinsulinemia exacerbates ovarian inflammation and oxidative stress, further impairing ovarian function and follicular development.

**Therapeutic Implications:**
Targeting insulin resistance and hyperinsulinemia is a key therapeutic strategy for managing PCOS and improving reproductive outcomes. Lifestyle interventions, including diet modification, weight loss, and regular physical activity, are first-line approaches for improving insulin sensitivity and reducing hyperinsulinemia in women with PCOS [16]. Pharmacological interventions, such as insulin-sensitizing agents (e.g., metformin) and antiandrogens (e.g., spironolactone), may be prescribed to further mitigate insulin resistance and alleviate hyperandrogenism in PCOS. By addressing insulin resistance and hyperinsulinemia, clinicians can improve ovulatory function, restore menstrual regularity, and enhance fertility outcomes in women with PCOS.

**Impact of Hormonal Imbalances: Androgens, Estrogens, and Progesterone**
Hormonal imbalances play a central role in the pathogenesis of Polycystic Ovarian Syndrome (PCOS), contributing to the clinical manifestations and reproductive complications associated with the disorder. PCOS
is characterized by hyperandrogenism, elevated androgen levels, and disrupted estrogen and progesterone dynamics, which impact ovarian function, menstrual regularity, and fertility [17]. This section explores the impact of hormonal imbalances on PCOS pathophysiology and their clinical implications.

**Hyperandrogenism:** Hyperandrogenism is a hallmark feature of PCOS, observed in approximately 70-80% of affected individuals. Androgens, including testosterone, androstenedione, and dehydroepiandrosterone sulfate (DHEAS), are predominantly produced by the ovaries and adrenal glands and play critical roles in regulating ovarian function and secondary sexual characteristics. In PCOS, hyperandrogenism results from dysregulated ovarian androgen synthesis, increased adrenal androgen secretion, and impaired androgen metabolism and clearance. Elevated androgen levels contribute to the clinical manifestations of PCOS, including hirsutism (excessive hair growth), acne, and androgenic alopecia (male-pattern baldness). Furthermore, hyperandrogenism disrupts follicular development and ovulation, leading to anovulatory cycles and menstrual irregularities observed in women with PCOS [18].

**Estrogen Imbalance:** Estrogen dynamics are altered in PCOS, with disruptions in estrogen synthesis, metabolism, and clearance contributing to the pathophysiology of the disorder. While estrogen levels may be normal or elevated in PCOS, the ratio of estrogen to progesterone is often dysregulated, leading to unopposed estrogen stimulation of the endometrium and increased risk of endometrial hyperplasia and carcinoma. Estrogen excess may result from increased aromatase activity in adipose tissue, leading to peripheral conversion of androgens to estrogens, or impaired hepatic estrogen metabolism and clearance. Estrogen imbalance contributes to menstrual irregularities, including oligomenorrhea and amenorrhea, observed in women with PCOS [17-18].

**Progesterone Deficiency:** Progesterone deficiency is a common feature of PCOS, resulting from anovulatory cycles and inadequate corpus luteum function. In the absence of ovulation, the corpus luteum fails to develop, leading to reduced progesterone production and luteal phase defects. Progesterone deficiency disrupts the normal menstrual cycle and contributes to irregular bleeding patterns, including breakthrough bleeding and prolonged anovulatory bleeding, observed in women with PCOS. Furthermore, inadequate progesterone levels may impair endometrial maturation and receptivity, leading to infertility and pregnancy complications in women with PCOS [16-17].

**Therapeutic Implications:** Targeting hormonal imbalances is essential for managing the clinical manifestations and reproductive complications associated with PCOS. Hormonal contraceptives, including combined oral contraceptives (COCs) and progestin-only contraceptives, are commonly prescribed to regulate menstrual cycles, suppress androgen production, and protect the endometrium against hyperplasia and carcinoma in women with PCOS. Antiandrogen medications, such as spironolactone and cyproterone acetate, may be used to alleviate hirsutism and acne by blocking androgen receptors and reducing androgen levels. Additionally, ovulation induction therapies, including clomiphene citrate and letrozole, are employed to stimulate follicular development and induce ovulation in women with anovulatory PCOS. By addressing hormonal imbalances, clinicians can improve reproductive outcomes and quality of life in women with PCOS [16-18].

**Clinical Manifestations of Polycystic Ovarian Syndrome (PCOS)**

Polycystic Ovarian Syndrome (PCOS) is a complex endocrine disorder characterized by a diverse array of clinical manifestations, reflecting its heterogeneous presentation and variable phenotypic expression. Common clinical features of PCOS include menstrual irregularities, hyperandrogenism, and polycystic ovarian morphology, which collectively contribute to the diagnostic criteria and management of the disorder. This section explores the clinical manifestations of PCOS in detail, including menstrual irregularities, hyperandrogenism, and polycystic ovarian morphology, and their implications for diagnosis and treatment.

**Menstrual Irregularities:** Menstrual irregularities are hallmark features of PCOS, affecting up to 75-85% of affected individuals. Women with PCOS commonly present with oligomenorrhea (infrequent menstrual periods) or amenorrhea (absence of menstrual periods), reflecting disturbances in ovarian function and menstrual cycle regulation. Oligomenorrhea is defined as menstrual cycles lasting longer than 35 days or fewer than eight menstrual periods per year, while amenorrhea is defined as the absence of menstrual periods for three consecutive months or more. Menstrual irregularities in PCOS result from anovulatory cycles, wherein follicular development and ovulation are disrupted due to hormonal imbalances and ovarian dysfunction. In the absence of ovulation, there is inadequate production of progesterone, leading to delayed or absent withdrawal bleeding and irregular shedding of the endometrial lining [19]. Menstrual irregularities in PCOS can have significant implications for reproductive health, including infertility, endometrial hyperplasia, and an increased risk of endometrial carcinoma. Therefore, the assessment and management of menstrual
irregularities are essential components of PCOS care, aimed at restoring ovulatory function and promoting menstrual regularity.

**Hyperandrogenism:** Hyperandrogenism is a cardinal feature of PCOS, characterized by elevated levels of androgens (male hormones) in circulation and clinical manifestations such as hirsutism, acne, and male-pattern baldness. Androgens, including testosterone, androstenedione, and dehydroepiandrosterone sulfate (DHEAS), are predominantly produced by the ovaries and adrenal glands and play critical roles in regulating ovarian function and secondary sexual characteristics [17]. In women with PCOS, hyperandrogenism results from dysregulated ovarian androgen synthesis, increased adrenal androgen secretion, and impaired androgen metabolism and clearance. Clinical manifestations of hyperandrogenism vary widely among affected individuals and may include:

**Hirsutism:** Hirsutism refers to excessive hair growth in a male-pattern distribution, including the face, chest, back, and abdomen. Hirsutism affects up to 70-80% of women with PCOS and can have significant psychological and social implications, leading to decreased quality of life and body image dissatisfaction. Hirsutism results from increased androgen-mediated stimulation of hair follicles, leading to the production of terminal hair in androgen-sensitive areas [20].

**Acne:** Acne vulgaris, a common dermatological manifestation of PCOS, affecting up to 30-40% of affected individuals. Acne in PCOS is characterized by inflammatory and non-inflammatory lesions, including papules, pustules, and comedones, typically localized to the face, chest, and back. Androgens stimulate sebaceous gland activity and keratinocyte proliferation, leading to increased sebum production, follicular hyperkeratinization, and inflammation, contributing to the development of acne lesions [21].

**Male-Pattern Baldness:** Male-pattern baldness, or androgenic alopecia, is characterized by progressive hair thinning and loss in a characteristic pattern, typically affecting the frontal and vertex regions of the scalp. Androgenic alopecia is observed in approximately 30-40% of women with PCOS and results from androgen-mediated miniaturization of hair follicles, leading to reduced hair density and diameter. Androgens exert their effects on hair follicles by binding to androgen receptors in the dermal papilla cells, disrupting the hair growth cycle and promoting follicular miniaturization [20-21].

The clinical manifestations of hyperandrogenism in PCOS can have significant psychosocial implications, including reduced self-esteem, depression, and anxiety, particularly in women with severe hirsutism or acne. Therefore, the assessment and management of hyperandrogenism are essential components of PCOS care, aimed at alleviating symptoms, improving cosmetic outcomes, and addressing underlying hormonal imbalances.

**Polycystic Ovarian Morphology:** Polycystic ovarian morphology is a key diagnostic criterion for PCOS, defined by the presence of multiple small ovarian follicles (2-9 mm in diameter) arranged peripherally around a dense, echogenic stroma on transvaginal ultrasound imaging. Polycystic ovaries are observed in approximately 90-95% of women with PCOS and reflect disturbances in ovarian follicular development and ovulation [22]. The exact pathophysiology underlying polycystic ovarian morphology in PCOS remains incompletely understood but is thought to involve dysregulated folliculogenesis, increased ovarian androgen secretion, and impaired follicular maturation and ovulation. The accumulation of small antral follicles within the ovaries results from arrested follicular development and reduced follicular atresia, leading to the characteristic appearance of polycystic ovaries on ultrasound imaging.

In addition to the diagnostic significance, polycystic ovarian morphology in PCOS is associated with an increased risk of metabolic dysfunction, including insulin resistance, dyslipidemia, and cardiovascular disease. Women with PCOS and polycystic ovarian morphology may also experience more severe clinical manifestations, including hyperandrogenism and menstrual irregularities, compared to those without polycystic ovaries [21]. Therefore, the assessment of ovarian morphology is an essential component of PCOS evaluation, providing valuable diagnostic information and guiding treatment decisions.

PCOS is a complex endocrine disorder characterized by a diverse array of clinical manifestations, including menstrual irregularities, hyperandrogenism, and polycystic ovarian morphology. Menstrual irregularities, such as oligomenorrhea and amenorrhea, reflect disruptions in ovarian function and hormonal regulation and can have significant implications for reproductive health. Hyperandrogenism, manifested by hirsutism, acne, and male-pattern baldness, is a cardinal feature of PCOS and results from dysregulated androgen production and action [12]. Polycystic ovarian morphology, observed on ultrasound imaging, is a key diagnostic criterion for PCOS and reflects disturbances in ovarian follicular development and ovulation. Comprehensive assessment
and management of the clinical manifestations of PCOS are essential for improving patient outcomes and addressing the underlying hormonal and metabolic imbalances associated with the disorder.

**Diagnosis and Diagnostic Criteria of PCOS**

Polycystic Ovarian Syndrome (PCOS) is a complex endocrine disorder characterized by heterogeneous clinical manifestations, making its diagnosis challenging. Over the years, several diagnostic criteria have been proposed to standardize the diagnosis of PCOS and guide clinical management. This section discusses the diagnostic criteria for PCOS, including the Rotterdam criteria, challenges and controversies in diagnosis, and the role of laboratory tests in confirming the diagnosis.

**Rotterdam Criteria:**
The Rotterdam criteria, established in 2003 during a consensus workshop sponsored by the European Society for Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM), represent the most widely accepted diagnostic criteria for PCOS [15]. According to the Rotterdam criteria, a diagnosis of PCOS requires the presence of at least two out of three criteria:

**Hyperandrogenism:** Clinical and/or biochemical evidence of hyperandrogenism, including hirsutism, acne, and male-pattern baldness, or elevated levels of serum androgens (e.g., testosterone, free testosterone, or DHEAS).

**Oligo-Anovulation:** Menstrual irregularities, such as oligomenorrhea (menstrual cycles longer than 35 days) or amenorrhea (absence of menstrual periods for three or more consecutive months), indicating anovulation or oligo-ovulation.

**Polycystic Ovarian Morphology:** The presence of polycystic ovarian morphology on ultrasound imaging, characterized by the presence of 12 or more small follicles (2-9 mm in diameter) arranged peripherally around the ovarian stroma or increased ovarian volume (>10 mL).

According to the Rotterdam criteria, the exclusion of other disorders that mimic PCOS, such as congenital adrenal hyperplasia, androgen-secreting tumors, and hyperprolactinemia, is essential to confirm the diagnosis. The Rotterdam criteria allow for the classification of PCOS phenotypes based on the predominant clinical features, including phenotype A (hyperandrogenism and oligo-anovulation), phenotype B (hyperandrogenism and polycystic ovarian morphology), and phenotype C (oligo-anovulation and polycystic ovarian morphology) [16].

**Challenges and Controversies in PCOS Diagnosis:**

Despite the widespread adoption of the Rotterdam criteria, there are several challenges and controversies associated with the diagnosis of PCOS, including:

**Phenotypic Heterogeneity:** PCOS is a heterogeneous disorder with variable clinical presentations, making its diagnosis challenging. Some women with PCOS may present with classic symptoms of hyperandrogenism and oligo-anovulation, while others may exhibit predominantly metabolic features, such as insulin resistance and obesity. The phenotypic heterogeneity of PCOS complicates diagnosis and classification and may result in underdiagnosis or misdiagnosis of the disorder [14].

**Overdiagnosis and Overtreatment:** The broad diagnostic criteria for PCOS, particularly the inclusion of polycystic ovarian morphology as a diagnostic criterion, may lead to overdiagnosis and overtreatment of the disorder. Many women with polycystic ovarian morphology on ultrasound imaging may not exhibit clinical manifestations of hyperandrogenism or menstrual irregularities and may not require medical intervention. Overdiagnosis and overtreatment of PCOS can have significant psychological and economic consequences for patients and may lead to unnecessary medical interventions and healthcare costs [16].

**Lack of Consensus on Diagnostic Thresholds:** There is ongoing debate and lack of consensus regarding the diagnostic thresholds for hyperandrogenism, menstrual irregularities, and polycystic ovarian morphology in PCOS. The interpretation of hormonal assays for androgens, such as testosterone and DHEAS, may vary among laboratories, leading to inconsistencies in diagnosis. Similarly, the definition of oligo-anovulation and the criteria for assessing polycystic ovarian morphology on ultrasound imaging may vary among clinicians, contributing to diagnostic variability and uncertainty [15].

**Role of Laboratory Tests:**

Laboratory tests play a crucial role in confirming the diagnosis of PCOS and evaluating associated metabolic
and hormonal abnormalities [18]. Key laboratory tests used in the diagnosis of PCOS include:

**Hormonal Profiling:** Measurement of serum levels of androgens (e.g., testosterone, free testosterone, DHEAS), gonadotropins (e.g., LH, FSH), and sex hormone-binding globulin (SHBG) can provide valuable information regarding hormonal imbalances associated with PCOS. Elevated levels of androgens, particularly testosterone and DHEAS, are indicative of hyperandrogenism, while an elevated LH-to-FSH ratio (>2:1) suggests dysregulated gonadotropin secretion.

**Imaging Studies:** Transvaginal ultrasound imaging is commonly used to assess ovarian morphology and identify the presence of polycystic ovaries. The diagnostic criteria for polycystic ovarian morphology on ultrasound imaging include the presence of 12 or more small follicles (2-9 mm in diameter) arranged peripherally around the ovarian stroma or increased ovarian volume (>10 mL). Additionally, imaging studies, such as pelvic ultrasound and magnetic resonance imaging (MRI), may be used to evaluate for other pelvic pathology and exclude ovarian or adrenal tumors mimicking PCOS.

**Biomarkers:** Emerging biomarkers, such as anti-Müllerian hormone (AMH) and adipokines (e.g., adiponectin, leptin), have shown promise in aiding the diagnosis and characterization of PCOS. AMH, a marker of ovarian reserve, is elevated in women with PCOS and may correlate with the severity of ovarian dysfunction and polycystic ovarian morphology. Adipokines, secreted by adipose tissue, play a role in metabolic regulation and insulin sensitivity and may be dysregulated in women with PCOS, providing insights into the metabolic phenotype of the disorder.

The diagnosis of Polycystic Ovarian Syndrome (PCOS) is based on a combination of clinical, biochemical, and imaging criteria, with the Rotterdam criteria representing the most widely accepted diagnostic framework. Challenges and controversies in PCOS diagnosis, including phenotypic heterogeneity, overdiagnosis.

**Management Strategies for PCOS**

Polycystic Ovarian Syndrome (PCOS) is a complex endocrine disorder that requires a multifaceted approach to management. Treatment goals in PCOS aim to alleviate symptoms, improve metabolic and hormonal imbalances, restore ovulatory function, and address reproductive concerns. This section discusses various management strategies for PCOS, including lifestyle modifications, pharmacological interventions, and assisted reproductive technologies [1].

**Lifestyle Modifications:** Lifestyle modifications, including dietary changes, regular exercise, and weight management, play a crucial role in the management of PCOS, particularly in addressing metabolic abnormalities and promoting overall health and well-being.

**Diet:** Dietary interventions focus on optimizing nutrient intake, promoting weight loss, and improving insulin sensitivity in women with PCOS. The Mediterranean diet, characterized by high consumption of fruits, vegetables, whole grains, lean proteins, and healthy fats (e.g., olive oil, nuts, seeds), has been shown to improve metabolic parameters and menstrual regularity in women with PCOS. Additionally, low-glycemic index (GI) and low-carbohydrate diets may help stabilize blood sugar levels and reduce insulin resistance in PCOS. Dietary counseling by a registered dietitian or nutritionist can provide personalized recommendations tailored to individual needs and preferences.

**Exercise:** Regular physical activity is essential for weight management, insulin sensitivity, and overall cardiovascular health in women with PCOS. Aerobic exercise, such as brisk walking, cycling, swimming, or jogging, helps burn calories, improve insulin sensitivity, and reduce abdominal adiposity. Resistance training, including strength training and weightlifting, can increase muscle mass, metabolic rate, and insulin sensitivity, thereby aiding in weight loss and glucose control. The American College of Obstetricians and Gynecologists (ACOG) recommends at least 150 minutes of moderate-intensity aerobic exercise or 75 minutes of vigorous-intensity aerobic exercise per week for women with PCOS.

**Weight Management:** Obesity and excess body weight are common comorbidities in PCOS and exacerbate insulin resistance, hyperandrogenism, and menstrual irregularities. Weight loss through caloric restriction, dietary modifications, and increased physical activity can improve metabolic parameters, restore ovulatory function, and enhance fertility outcomes in women with PCOS. Even modest weight loss of 5-10% of body weight has been shown to improve insulin sensitivity, reduce androgen levels, and promote menstrual regularity in women with PCOS. Behavioral interventions, such as cognitive-behavioral therapy (CBT) and motivational interviewing, can support sustainable lifestyle changes and long-term weight management in women with PCOS.
**Pharmacological Interventions:** Pharmacological interventions are often used in conjunction with lifestyle modifications to address hormonal imbalances, menstrual irregularities, and metabolic disturbances in PCOS.

**Oral Contraceptives:** Combined oral contraceptives (COCs) containing estrogen and progestin are commonly prescribed to regulate menstrual cycles, suppress ovarian androgen production, and alleviate symptoms of hyperandrogenism, such as hirsutism and acne, in women with PCOS. COCs inhibit gonadotropin secretion, reduce ovarian androgen synthesis, and increase sex hormone-binding globulin (SHBG) levels, thereby decreasing free testosterone levels and improving androgenic symptoms. Additionally, COCs provide endometrial protection against hyperplasia and carcinoma in women with PCOS-related menstrual irregularities.

**Antiandrogens:** Antiandrogen medications, such as spironolactone and cyproterone acetate, are used adjunctively with COCs or as monotherapy to target androgen-mediated symptoms, including hirsutism, acne, and male-pattern baldness, in women with PCOS. These medications block androgen receptors, inhibit androgen synthesis, and reduce androgen levels, thereby improving cosmetic outcomes and quality of life in affected individuals. However, antiandrogens should be used with caution in women of reproductive age due to teratogenic effects and potential adverse effects on fertility [1, 9].

**Insulin-Sensitizing Agents:** Insulin-sensitizing agents, such as metformin and thiazolidinediones (TZDs), are commonly prescribed to improve insulin sensitivity, reduce hyperinsulinemia, and restore ovulatory function in women with PCOS, particularly those with insulin resistance or impaired glucose tolerance. Metformin, a first-line medication for PCOS, inhibits hepatic gluconeogenesis, enhances peripheral glucose uptake, and improves insulin signaling, thereby lowering fasting insulin levels and reducing androgen production. TZDs, such as pioglitazone, improve insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), leading to enhanced glucose uptake and adipocyte differentiation. Insulin-sensitizing agents may also have beneficial effects on menstrual regularity, ovulation induction, and fertility outcomes in women with PCOS [13].

**Assisted Reproductive Technologies:** Assisted reproductive technologies (ART), including ovulation induction, in vitro fertilization (IVF), and oocyte cryopreservation, may be utilized in women with PCOS experiencing infertility or subfertility.

**Ovulation Induction:** Ovulation induction aims to stimulate follicular development and induce ovulation in women with PCOS who are anovulatory or oligo-ovulatory. Gonadotropin therapy, including follicle-stimulating hormone (FSH) and human chorionic gonadotropin (hCG), is commonly used to promote follicular growth and induce ovulation in women with PCOS. Clomiphene citrate, a selective estrogen receptor modulator (SERM), is another first-line medication for ovulation induction in PCOS, acting by blocking estrogen receptors in the hypothalamus and pituitary gland, leading to increased gonadotropin secretion and follicular recruitment [19].

**In Vitro Fertilization (IVF):** In vitro fertilization (IVF) may be recommended for women with PCOS who fail to conceive with conventional ovulation induction therapies or have other infertility factors. IVF involves controlled ovarian hyperstimulation (COH) to induce multifollicular development, followed by transvaginal oocyte retrieval, fertilization in the laboratory, and embryo transfer into the uterus. IVF allows for the manipulation of ovarian response and precise timing of oocyte retrieval, offering high success rates in achieving pregnancy in women with PCOS-related infertility [20].

**Oocyte Cryopreservation:** Oocyte cryopreservation, or egg freezing, may be considered for women with PCOS who wish to preserve their fertility for future reproductive purposes. Ovarian stimulation and oocyte retrieval are performed as part of the oocyte cryopreservation process, followed by vitrification of mature oocytes for long-term storage. Oocyte cryopreservation offers the opportunity for delayed childbearing and fertility preservation in women with PCOS undergoing medical treatments or facing age-related declines in ovarian reserve [17].

In conclusion, the management of Polycystic Ovarian Syndrome (PCOS) requires a comprehensive approach encompassing lifestyle modifications, pharmacological interventions, and assisted reproductive technologies tailored to individual needs and goals. Lifestyle modifications, including dietary changes, exercise, and weight management, are essential for improving metabolic health and promoting overall well-being in women with PCOS. Pharmacological interventions, such as oral contraceptives, antiandrogens, and insulin-sensitizing agents, target hormonal imbalances and menstrual irregularities associated with PCOS.
2. Conclusion

Polycystic Ovarian Syndrome (PCOS) presents a complex clinical challenge characterized by heterogeneous manifestations, including menstrual irregularities, hyperandrogenism, and polycystic ovarian morphology. Throughout this discussion, it becomes evident that effective management of PCOS demands a multifaceted approach addressing its diverse array of symptoms and underlying hormonal and metabolic imbalances. The management of PCOS begins with lifestyle modifications, emphasizing dietary changes, regular exercise, and weight management. These interventions not only improve metabolic parameters but also play a crucial role in promoting overall health and well-being, ultimately contributing to better outcomes for individuals with PCOS. Pharmacological interventions, such as oral contraceptives, antiandrogens, and insulin-sensitizing agents, offer additional therapeutic options to target specific aspects of PCOS, including menstrual irregularities, hyperandrogenism, and insulin resistance. However, it is essential to consider individual patient characteristics and preferences when selecting pharmacological treatments, as well as potential risks and benefits associated with each intervention. Assisted reproductive technologies, including ovulation induction, in vitro fertilization (IVF), and oocyte cryopreservation, provide valuable options for individuals with PCOS experiencing infertility or seeking fertility preservation. These technologies offer hope for achieving pregnancy and expanding reproductive options for women with PCOS, contributing to improved quality of life and family-building outcomes.

Despite significant advancements in the understanding and management of PCOS, several challenges and controversies persist. Phenotypic heterogeneity, diagnostic variability, and overdiagnosis remain key areas of concern, highlighting the need for standardized diagnostic criteria and individualized approaches to care. Additionally, ongoing research is needed to elucidate the underlying pathophysiology of PCOS, identify novel therapeutic targets, and develop more effective treatment strategies for this complex disorder.

In addressing these challenges, interdisciplinary collaboration among healthcare providers, including gynecologists, endocrinologists, nutritionists, and mental health professionals, is essential to ensure comprehensive and holistic care for individuals with PCOS. By integrating medical management with lifestyle interventions, psychological support, and reproductive counseling, healthcare teams can optimize outcomes and improve the overall well-being of patients with PCOS. Looking ahead, continued efforts in research, education, and advocacy are crucial for raising awareness about PCOS, promoting early detection and intervention, and advocating for improved access to care for affected individuals worldwide. By working together to advance our understanding and management of PCOS, we can empower individuals with this condition to lead healthier lives and achieve their reproductive goals.

In summary, PCOS represents a significant healthcare challenge with far-reaching implications for affected individuals and society as a whole. Through comprehensive management approaches addressing lifestyle factors, pharmacological interventions, and assisted reproductive technologies, we can strive to improve outcomes, enhance quality of life, and ultimately empower individuals with PCOS to live their lives to the fullest.

Ethics approval: Sumatera Medical Journal (SUMEJ) is a peer-reviewed electronic international journal. This statement below clarifies ethical behavior of all parties involved in the act of publishing an article in Sumatera Medical Journal (SUMEJ), including the authors, the chief editor, the Editorial Board, the peer-reviewer and the publisher (TALENTA Publisher Universitas Sumatera Utara). This statement is based on COPE’s Best Practice Guidelines for Journal Editors.

Authors contributions: All authors contributed to the design and implementation of the research, data analysis, and finalizing the manuscript.

Funding: No funding.

Disclosure: No conflict of interest.

References
and nuclear medicine and morphology; which is more accurate in making the diagnosis?!

H.I.

no.

hormone profiles and clinical findings

S.

pathophysiology and management

P.M.

n

A.C.H.

no.

rats

Hyperglycemia compensates for diet

perspective

V.

Metabolism

G.A.

no.

disturbance of hypothalamic

X.

ovary syndrome

N.E.

1,

cancer management

D.

diabetes

R.

anti

P.K.

horizon

nanotechnology to herbal antioxidants as improved phytomedicine: An expanding

Y.

o.

01, pp. 005

Zandi,

4,

pp.

Dunaif,

2020.

Elsadawy, &

Prabhakar, &

P.K.

acne combination by using in

In

vol.

vol.

275

vol.

33

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,

Serrano,